Company profile for Ankyra Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Ankyra is developing a platform to significantly improve both the safety and efficacy of cytokine immunotherapies for cancer. Systemic dosing of these powerful immune stimulants has historically been limited by broad immune activation and toxicity. We have developed methods to localize cytokines specifically and persistently within tumors thereby creating intense hot spots of inflammation that activate a comprehensive anti-tum...
Ankyra is developing a platform to significantly improve both the safety and efficacy of cytokine immunotherapies for cancer. Systemic dosing of these powerful immune stimulants has historically been limited by broad immune activation and toxicity. We have developed methods to localize cytokines specifically and persistently within tumors thereby creating intense hot spots of inflammation that activate a comprehensive anti-tumor immune response. Our mission is to translate this approach into the clinic and demonstrate superior efficacy compared to available options.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
83 Newbury Street 4th Floor Boston, MA 02116
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251215507385/en/Ankyra-Appoints-Sailaja-Battula-PhD-as-Chief-Scientific-Officer-CSO

BUSINESSWIRE
15 Dec 2025

https://www.businesswire.com/news/home/20251117754232/en/Ankyra-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1b-Trial-Evaluating-First-in-Class-Anchored-Immunotherapy-in-Combination-with-Immune-Checkpoint-Blockade-in-Patients-with-Lung-Cancer

BUSINESSWIRE
17 Nov 2025

https://www.businesswire.com/news/home/20251104335799/en/Ankyra-Announces-Publication-of-Phase-1-Clinical-Data-and-Will-Present-at-the-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting

BUSINESSWIRE
04 Nov 2025

https://www.businesswire.com/news/home/20250428550798/en/Ankyra-Therapeutics-Announces-Phase-1-Clinical-Data-at-the-2025-AACR-Annual-Meeting-and-the-first-patient-has-been-dosed-with-tolododekin-alfa-and-cemiplimab

BUSINESSWIRE
28 Apr 2025

https://www.businesswire.com/news/home/20241105939527/en

BUSINESSWIRE
05 Nov 2024

https://www.businesswire.com/news/home/20240923495721/en

BUSINESSWIRE
23 Sep 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty